Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer (original) (raw)

Clinical Oncology/Epidemiology

British Journal of Cancer volume 65, pages 118–121 (1992)Cite this article

Abstract

Of 221 patients with breast cancer of known epidermal growth factor receptor (EGFR) and oestrogen receptor (ER) status, 99 had developed recurrences during the period of follow-up (range 3-60 months, median 24 months). Of these, 72 received endocrine therapy as first-line treatment for relapse. Immunohistochemical assessment of c-erbB-2 protein product expression was made using paraffin-embedded tumour tissue from 65 of these 72 patients. Including patients whose disease remained stable for more than 6 months with those showing an objective response (CR or PR for more than 3 months), only one (7%) of 14 c-erbB-2 positive tumours responded to endocrine manipulation compared with 19 (37%) of 51 c-erbB-2 negative tumours (P less than 0.05). Coexpression of c-erbB-2 reduced the response rate of ER positive patients from 48% to 20% and of ER negative cases from 27% to 0% (P less than 0.01). EGFR and c-erbB-2 protein appeared to have additive effects in reducing the likelihood of response, and none of eight patients with EGFR positive, c-erbB-2 positive tumours derived benefit from endocrine therapy. The results of this study suggest that c-erbB-2 protein overexpression, a marker of poor prognosis in breast cancer, is associated with a lack of response to endocrine therapy on relapse, and particularly in combination with EGFR may be useful in directing therapeutic choices.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 24 print issues and online access

$259.00 per year

only $10.79 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Division of Pathology, University of Newcastle upon Tyne, UK
    C Wright

Authors

  1. C Wright
  2. S Nicholson
  3. B Angus
  4. JRC Sainsbury
  5. J Farndon
  6. J Cairns
  7. AL Harris
  8. CHW Horne

Rights and permissions

About this article

Cite this article

Wright, C., Nicholson, S., Angus, B. et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.Br J Cancer 65, 118–121 (1992). https://doi.org/10.1038/bjc.1992.22

Download citation

This article is cited by